Literature DB >> 6810854

Brain glucocerebrosidase in Gaucher's disease.

L B Daniels, P J Coyle, R H Glew, N S Radin, R S Labow.   

Abstract

Using glucocerebroside labeled with carbon 14 as the substrate, we determined that homogenates of brain tissue from both neuropathic and nonneuropathic cases of Gaucher's disease were profoundly deficient (more than 85%) in glucocerebrosidase activity. The beta-glucosidase activity, as measured with 4-methylumbelliferyl-beta-D-glucopyranoside as the substrate, in the homogenates of brain from four cases of Gaucher's disease was less sensitive to inhibition by conduritol B epoxide (CBE) when compared with normal brain beta-glucosidase. However, when homogenates were assayed with radiolabeled glucocerebroside as the substrate, no differential sensitivity toward CBE was indicated, suggesting the presence of an additional, CBE-insensitive, beta-glucosidase in brain tissue. Residual glucocerebrosidase activity partially purified from the brain of an adult with type 1 Gaucher's disease was activated threefold by gluconoyl hydrazine, whereas the same enzyme from control brain was unaffected, and eight times less sensitive to gluconolactone inhibition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810854     DOI: 10.1001/archneur.1982.00510210020005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  6 in total

1.  Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms.

Authors:  G T Besley; M Elleder
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Authors:  You-Hai Xu; Rachel Reboulet; Brian Quinn; Joerg Huelsken; David Witte; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

3.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

4.  Characterization of the phospholipid requirement of a rat liver beta-glucosidase.

Authors:  A Basu; R H Glew
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

Review 5.  Treatment of Gaucher disease with an enzyme inhibitor.

Authors:  N S Radin
Journal:  Glycoconj J       Date:  1996-04       Impact factor: 2.916

6.  Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process.

Authors:  H Hůlková; J Ledvinová; H Poupetová; A Kohout; V Malinová; M Elleder
Journal:  J Inherit Metab Dis       Date:  2009-06-26       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.